On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“ Twasn't my quote, as implied by you. Nice try... Trace it back... not difficult.”
Quoted but not questioned, corrected or refuted. You own it. It’s part of your post.
Same bullshit different day. Your example is not unprecedented; it’s as common as spring showers or a cloudless summer day.
The number of shares has never been under 100 million for IPIX or CTIX. The company began as CTIX with issuing 100 million shares. From 100 million shares to under 500 million shares in 12 years while funding a dozen trials is actually somewhat rare or even unprecedented in biopharma land.
What part of double blind do you not understand? I will be happy to explain it so you can understand why no one knows anything, not even lab scientists, whatever you think “lab scientists” means.
Lol thanks for that.
Yes, seems to be all smoke and bluster.
“ B was given to a sicky who is still on a ventilator - so really didn't work ”
You can’t claim that because you don’t know the patient’s condition before and after. If the patient had the same deep lung damage that 10% of hospitalized patients wind up with, said patient would be on a ventilator for weeks. So, if you’re not an attending physician, you don’t know shit about the case.
Please post a link to the source of whatever it is you’re claiming. All I get are regulatory papers to read through. Yes those papers are very detailed on how to submit boundless paperwork into the bureaucracy, but nothing actually useful. Seems like smoke and bluster to me.
The raw data isn’t a secret.
The raw data is not secret. The blind is to which patients the data is attributed.
The data isn’t secret. Only to which group the data can be attributed.
I wouldn’t substitute “might” for “is” because “is” would be wrong. The signal in the data can come from anything including outlier patient recovery.
There can be signals from raw blinded data. It’s not secret data, it simply means it’s not attributed yet to any group. A signal would be the entire 120 patient data shows faster than expected recovery. That’s a signal.
Agree. There would need to be signals it might be working. The FDA does not grant compassionate use for drugs at the end of a Phase 2 trial without some indication of efficacy from the still blinded or unblinded data.
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin’s Broad-Spectrum Antiviral Properties
WAKEFIELD, MA / September 23, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897), as well as related news.
Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October. The Company looks forward to the data to learn if Brilacidin’s multiple properties translate into meaningful clinical results, given the unmet need for COVID-19 therapeutics and ongoing pandemic.
In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
For more details on the Company's Expanded Access policy, please visit:
https://www.ipharminc.com/expanded-access-and-compassionate-use
Brilacidin in vitro antiviral research remains ongoing at multiple universities. New preliminary data from one academic laboratory show Brilacidin is active against adenoviruses—a non-enveloped virus—complementing earlier data showing potent Brilacidin inhibition of different strains of coronaviruses, alphaviruses and bunyaviruses (enveloped viruses). A paper from this lab on Brilacidin’s broad-spectrum antiviral effect in multiple virus families is being prepared. Separate scientific papers also are underway from two other academic research groups supporting Brilacidin’s antiviral properties and providing insight into Brilacidin’s mechanisms of action.
I think it’s Putin buying. Lol
“If there’s $10 million on hand, it’s a good thing. And, I think there is.” ???
Is that enough conditional?
Absolutely not true. While vaccines remain effective in keeping people out of hospitals (92-97% effective), and keeping hospitalized patients from dying (85-92% effective of those hospitalized), it efficacy is waning. So there will continue to be a need for therapeutics for those unvaccinated or those contracting break through infections. SARS-CoV-2 will be with us for at least another year and likely 2 years.
I’ve already answered that question.
It’s not “moving goal posts” to point out flaws in reasoning and explain the purpose of scientific conferences to those who misunderstand or misrepresent those purposes.
Why? So non-investors can complain that he’s releasing PRs with information we already know? Good strategy. /s
The CEO booked a conference to report to a scientific community that has little or no awareness of Brilacidin’s antiviral activity. That’s the purpose of those types of conferences. We investors already know that information.
What narrative? You mean the one where we already know Brilacidin kills viruses in culture? You mean that narrative?
Without the conference there is nothing to report. As you note, they were going to discuss antiviral activity in cultures. We investors already know that Brilacidin destroys viruses in culture.
The purpose was to make known Brilacidin, not to present data from the current trial. Since the data lock has not yet been reported, it’s unlikely that there would be anything new to report to shareholders. So, without the conference, there is nothing to report.
I prefer not to chase conspiracy theories. I also prefer to debunk nonsense that keeps coming back around even after being fully debunked and discredited. I prefer to wait for Brilacidin to either prove clinical efficacy or go the way of ivermectin and hydroxychloroquine when it comes to SARS-CoV-2 infection treatment.
Ivermectin doesn’t work. It’s the new hydroxychloroquine.
Probably very little will happen to “Covid stocks” since Pfizer and Moderna vaccines only keep 86% of Covid patients out of the hospital. So, there is still a strong need for a therapeutic that can treat breakthrough cases not to mention the 40% of the population still unvaccinated.
Shareholder News: Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research
WAKEFIELD, MA – August 2, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Company’s defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.
Brilacidin antiviral research updates are provided below:
2021 Military Health System Research Symposium (MHSRS): Due to rising COVID-19 infections tied to the spread of SARS-CoV-2 variants, the U.S. Department of Defense (as the symposium sponsor) last Thursday cancelled the event that was to be held in Orlando, Florida. The Company will be discussing with George Mason University scientists, who were scheduled to present Brilacidin research on non-SARS-CoV-2 viruses, appropriate next steps for potential release of these findings.
Brilacidin SARS-CoV-2 Manuscript: Scientists conducting laboratory testing of Brilacidin, in particular its ability to block entry of SARS-CoV-2 into human cells, have submitted their research findings for peer-review publication. These data include insights into Brilacidin’s antiviral mechanisms of action and Brilacidin activity against the Alpha (B.1.1.7) and Gamma (P.1) SARS-CoV-2 variants.
Related, the Company is in queue for in vitro testing of Brilacidin against the Delta (B.1.67.2) variant, which is showing increased transmissibility regardless of vaccination status according to reports of new CDC data. The Delta variant is now considered more transmissible than MERS, SARS, Ebola, the common cold, the seasonal flu, and can be caught as easily as chickenpox. CDC director Dr. Rochelle Walensky commented: “It’s one of the most transmissible viruses we know of.”
Brilacidin Human Coronavirus (H-CoV) Research: Scientists conducting laboratory testing of Brilacidin in endemic H-CoV strains (OC43, 229E, NL63) have informed the Company that they are reviewing potential venues to disseminate their findings, including conferences, via publication or through public release by the Company. These data show Brilacidin inhibits different H-CoV strains, supporting Brilacidin as a pan-coronavirus agent.
“Taken together, the results from ongoing lab research into Brilacidin’s antiviral properties by different groups of scientists only strengthens our belief in Brilacidin,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “With a highly contagious virus circulating throughout the world and continuing to mutate in dangerous ways, reducing the effectiveness of available COVID-19 treatments and vaccines, there is a global public health need to develop broad-spectrum antivirals. Our hope is that Brilacidin, which is showing an inherent ability to be resistant to viral mutations, can play a vital role in helping contain the spread of SARS-CoV-2, as the virus is likely to be an infectious disease challenge for years to come.”
About Brilacidin and COVID-19
Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19 (see NCT04784897). Innovation Pharma is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation. Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidin’s potential to be developed as a broad-spectrum antiviral. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at the link below.
Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271
https://www.mdpi.com/1999-4915/13/2/271/
Two independent Machine Learning studies identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin’s molecular properties.
A high viral load, with no symptoms, still means a lot of Delta gets shed in asymptomatic, inoculated people. It’s a new SARS-CoV-delta discovery, and it’s a condition not seen before in vaccines and other CoV variants, so the assumption of shedding is only not understood in its mechanism, not in the creation and production of a “Covid Mary” population infecting unvaccinated people.
If Brilacidin works, then the ideal is vaccinate and treat with B if breakout cases.
Weeks ago we were told that Putin wasn’t buying so the trial must be failure. So, with all the buying, and Putin knows everything, the trial must be a spectacular success. Hmmm.
Again, your post misrepresents clinical trials and the need to complete the study endpoints before unblinding the data and outcomes. Lots of emotionally charged language that has no place in the clinical development process.
It’s bullshit like your post that we wound up wasting time and effort, and money, looking at Hydroxychloroquine based on flawed early reports.
What part of double-blind is confusing to you? I would be happy to help with whatever in a blinded study seems unclear.
Not while it’s blinded. They only monitor adverse events.
There’s no data now, other than safety.
Putting this politely: the efficacy data is still blinded. The only data they have is safety, which was the interim report you keep going on about. No one knows anything. Not the doctors. Not Putin. A ridiculous assertion.
Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
* Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
* Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session
WAKEFIELD, MA – June 18, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral research related to Brilacidin has been accepted for an Oral Presentation at the 2021 Military Health System Research Symposium (MHSRS), taking place August 23-26, 2021, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL.
The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense. The presentation on Brilacidin will be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session. Out of nearly 2,300 submissions, approximately 20 percent were accepted for presentation.
New data supporting Brilacidin’s broad spectrum antiviral properties will be presented at the 2021 MHSRS conference, as well as during a separate oral presentation on Brilacidin to be delivered at the American Society of Virology’s 40th Annual Meeting, to be held in July.
TDA is back up and trading.